You just read:

Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease

News provided by

Viking Therapeutics, Inc

Nov 17, 2015, 07:30 ET